Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Arrowhead Pharmaceuticals In (ARWR)

490 + Investors. Track Smart Money conviction in ARWR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +61
Streak
5Q ▲
Buyers last Q
57%

Smart Money Signals — ARWR

Based on 501 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds added ARWR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
501 hedge funds hold ARWR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +78% more funds vs a year ago

fund count last 6Q
+220 new funds entered over the past year (+78% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 57% buying

290 buying223 selling
Last quarter: 290 funds bought or added vs 223 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+23 vs last Q)

new funds entering per quarter
Funds opening a new ARWR position: 65 → 133 → 106 → 129. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

46% of holders stayed for 2+ years

■ 46% conviction (2yr+) ■ 21% medium ■ 33% new
231 out of 501 hedge funds have held ARWR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +30% but shares only +7% — price-driven

Value
+30%
Shares
+6%
Last quarter: the total dollar value of institutional holdings rose +30%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

60 → 65 → 133 → 106 → 129 new funds/Q
New funds entering each quarter: 65 → 133 → 106 → 129. A growing number of institutions are discovering ARWR each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 60% veterans vs 33% newcomers

■ 60% veterans ■ 8% 1-2yr ■ 33% new
Entry-cohort mix of 516 holders: 309 (60%) are 2+ year veterans, 39 entered 1–2 years ago, and 168 (33%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 52% AUM from top-100 funds

52% from top-100 AUM funds
62 of 494 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in ARWR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.7
out of 10
Moderate Exit Risk
Exit risk score 4.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ARWR

In 2026 Q2, 290 hedge funds were net buyers of ARWR (129 opened a new position, 161 added to an existing one), while 223 reduced or exited (155 trimmed, 68 sold completely) — a 57% buyer ratio, indicating a slight buying edge. This marks 5 consecutive quarters of net institutional buying — a persistent conviction signal. 52% of total institutional value in ARWR is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +61 funds (more new holders than closures). Total institutional holders: 501.

Hedge Fund Ownership: ARWR

How many hedge funds hold ARWR — quarterly history vs. share price
Quarterly hedge fund ownership of ARWR vs. share price

Market Analysis: ARWR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ARWR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

18 top-rated funds 5 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
3.1
/ 10
conviction
Hedge Fund Positioning: ARWR
490 + Investors

Track Smart Money conviction in ARWR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 490 440 11.36%
13F Shares 121M 124M -2.32%
Total Value $9.72B $7.58B 28.35%
New Positions 127 106 +21
Increased Positions 157 164 -7
Closed Positions 70 70 -
Reduced Positions 148 119 +29
Total Calls 12 13 -7.69%
Total Puts 10 11 -9.09%
PUT/CALL Ratio 0.83 0.85 Neutral

Statistics: ARWR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

490 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ARWR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ARWR holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Western Financial Corp/CA 19.58% 820,239 $66.9M
2 Avoro Capital Advisors LLC 8.31% 11,355,555 $925.6M
3 M28 Capital Management LP 6.37% 36,851 $3.0M
4 Act Capital Management, LLC 5.86% 110,100 $9.0M
5 Privium Fund Management B.V. 3.51% 234,222 $19.1M
6 Wealth Effects LLC 3.24% 147,300 $12.0M
7 Vestal Point Capital, LP 3.00% 1,575,000 $128.4M
8 Siren, L.L.C. 2.83% 1,715,476 $139.8M
9 Evolutionary Tree Capital Management, LLC 2.21% 14,368 $1.2M
10 Tetragon Partners GP Ltd 1.67% 130,484 $10.6M
11 Exome Asset Management LLC 1.62% 32,214 $2.6M
12 Orion Investment Co 1.57% 65,831 $5.4M
13 Dorsey Wright & Associates 1.35% 97,466 $7.9M
14 Platinum Investment Management Ltd 1.30% 64,752 $5.3M
15 Summit Partners Public Asset Management, LLC 1.19% 830,247 $67.7M
16 Deerfield Management Company, L.P. 1.18% 1,389,055 $113.2M
17 Pinion Investment Advisors, LLC 1.16% 75,000 $6.1M
18 Rhenman & Partners Asset Management AB 0.98% 128,000 $10.4M
19 PFM Health Sciences, LP 0.92% 131,667 $10.7M
20 Fred Alger Management, LLC 0.90% 3,301,919 $269.1M
21 Ikarian Capital, LLC 0.88% 100,000 $8.2M
22 Baker BROS. Advisors LP 0.81% 1,992,783 $162.4M
23 Hood River Capital Management LLC 0.66% 1,120,747 $91.4M
24 Integral Health Asset Management, LLC 0.64% 200,000 $16.3M
25 Driehaus Capital Management LLC 0.64% 1,350,556 $110.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Arrowhead Pharmaceuticals In (ARWR)

What does the Smart Money Trend signal show for ARWR?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added ARWR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ARWR?

Slight buying edge — 57% buying: Last quarter: 290 funds bought or added vs 223 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ARWR holders?

Elite ownership — 52% AUM from top-100 funds: 62 of 494 holders are among the 100 largest funds by AUM, controlling 52% of total institutional value in ARWR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ARWR?

46% of holders stayed for 2+ years: 231 out of 501 hedge funds have held ARWR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →